# Phesgo

NDC: 50242-245
Generic name: pertuzumab, trastuzumab, and hyaluronidase-zzxf
Labeler / Manufacturer: Genentech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20200629

FDA application: BLA761170

## Active ingredients

- HYALURONIDASE (HUMAN RECOMBINANT): 30000 U/15mL
- PERTUZUMAB: 1200 mg/15mL
- TRASTUZUMAB: 600 mg/15mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"50242-245"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=50242-245
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da